caa a22 4500 477070175 CHVBK 20180405111423.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/BF01709367 doi (NATIONALLICENCE)springer-10.1007/BF01709367 Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:PolyC12U in the treatment of HIV infection [Elektronische Daten] [K. Thompson, D. Strayer, P. Salvato, C. Thompson, N. Klimas, A. Molavi, A. Hamill, Z. Zheng, D. Ventura, W. Carter] In this multicenter, randomized, double-blind study the activity of polyI:polyC12U administered with zidovudine was evaluated in the treatment of HIV infection. Thirty-six HIV-positive, pre-AIDS individuals (100-500 CD4+ cells/mm3) who had had at least six months of zidovudine therapy received polyI:polyC12U (400 or 700 mg) or placebo twice weekly with zidovudine. PolyI:polyC12U subjects with baseline CD4+ counts≥300/mm3 showed a trend towards reduced CD4+ loss versus placebo recipients. PolyI:polyC12U subjects were more likely to exhibit positive delayed-type hypersensitivity responses than placebo recipients. Placebo subjects crossing over to polyI:polyC12U therapy demonstrated improved CD4+ and delayed-type hypersensitivity responses. PolyI: polyC12U subjects with baseline CD4+ counts≥300/mm3 were less likely to develop AIDS than similar placebo subjects. PolyI:polyC12U therapy of HIV-positive subjects restored or stabilized immune function as indexed by delayed-type hypersensitivity reactivity and, in individuals with CD4+ counts>300/mm3, abrogated CD4+ loss and reduced disease progression. PolyI:polyC12U was generally well-tolerated in this zidovudine-treated population. No subject discontinued therapy due to an adverse reaction or aberrant laboratory parameter. MMV Medizin Verlag GmbH, 1996 Thompson K. Hemispherx Biopharma Incorporated, 1617 JFK Boulevard, Suite 660, 19103, Philadelphia, Pennsylvania, USA aut Strayer D. Department of Medicine, Medical College of Pennsylvania and Hahnemann University, MS 412 Broad and Vine Streets, 19102, Philadelphia, Pennsylvania, USA aut Salvato P. Houston Immunological Institute, Houston, Texas, USA aut Thompson C. Houston Immunological Institute, Houston, Texas, USA aut Klimas N. Immunology Clinic No. 4, Veterans Administration Medical Center, Miami, Florida, USA aut Molavi A. aut Hamill A. Nelson-Tebedo Community Clinic, Dallas, Texas, USA aut Zheng Z. Hemispherx Biopharma Incorporated, 1617 JFK Boulevard, Suite 660, 19103, Philadelphia, Pennsylvania, USA aut Ventura D. Hemispherx Biopharma Incorporated, 1617 JFK Boulevard, Suite 660, 19103, Philadelphia, Pennsylvania, USA aut Carter W. Hemispherx Biopharma Incorporated, 1617 JFK Boulevard, Suite 660, 19103, Philadelphia, Pennsylvania, USA aut European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/7(1996-07-01), 580-587 0934-9723 15:7<580 1996 15 10096 https://doi.org/10.1007/BF01709367 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01709367 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Thompson K. Hemispherx Biopharma Incorporated, 1617 JFK Boulevard, Suite 660, 19103, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 700 1- Strayer D. Department of Medicine, Medical College of Pennsylvania and Hahnemann University, MS 412 Broad and Vine Streets, 19102, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 700 1- Salvato P. Houston Immunological Institute, Houston, Texas, USA aut NATIONALLICENCE 700 1- Thompson C. Houston Immunological Institute, Houston, Texas, USA aut NATIONALLICENCE 700 1- Klimas N. Immunology Clinic No. 4, Veterans Administration Medical Center, Miami, Florida, USA aut NATIONALLICENCE 700 1- Molavi A. aut NATIONALLICENCE 700 1- Hamill A. Nelson-Tebedo Community Clinic, Dallas, Texas, USA aut NATIONALLICENCE 700 1- Zheng Z. Hemispherx Biopharma Incorporated, 1617 JFK Boulevard, Suite 660, 19103, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 700 1- Ventura D. Hemispherx Biopharma Incorporated, 1617 JFK Boulevard, Suite 660, 19103, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 700 1- Carter W. Hemispherx Biopharma Incorporated, 1617 JFK Boulevard, Suite 660, 19103, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/7(1996-07-01), 580-587 0934-9723 15:7<580 1996 15 10096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer